Methylation of cell-free circulating DNA in the diagnosis of cancer

Kristina Warton, Goli Samimi, Kristina Warton, Goli Samimi

Abstract

A range of molecular alterations found in tumor cells, such as DNA mutations and DNA methylation, is reflected in cell-free circulating DNA (circDNA) released from the tumor into the blood, thereby making circDNA an ideal candidate for the basis of a blood-based cancer diagnosis test. In many cancer types, mutations driving tumor development and progression are present in a wide range of oncogenes and tumor suppressor genes. However, even when a gene is consistently mutated in a particular cancer, the mutations can be spread over very large regions of its sequence, making evaluation difficult. This diversity of sequence changes in tumor DNA presents a challenge for the development of blood tests based on DNA mutations for cancer diagnosis. Unlike mutations, DNA methylation that can be consistently measured, as it tends to occur in specific regions of the DNA called CpG islands. Since DNA methylation is reflected within circDNA, detection of tumor-specific DNA methylation in patient plasma is a feasible approach for the development of a blood-based test. Aberrant circDNA methylation has been described in most cancer types and is actively being investigated for clinical applications. A commercial blood test for colorectal cancer based on the methylation of the SEPT9 promoter region in circDNA is under review for approval by the Federal Drug Administration (FDA) for clinical use. In this paper, we review the state of research in circDNA methylation as an application for blood-based diagnostic tests in colorectal, breast, lung, pancreatic and ovarian cancers, and we consider some of the future directions and challenges in this field. There are a number of potential circDNA biomarkers currently under investigation, and experience with SEPT9 shows that the time to clinical translation can be relatively rapid, supporting the promise of circDNA as a biomarker.

Keywords: cancer; circulating DNA; diagnosis; early detection; methylation; plasma DNA.

References

    1. Ahlquist D. A., Taylor W. R., Mahoney D. W., Zou H., Domanico M., Thibodeau S. N., et al. . (2012). The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin. Gastroenterol. Hepatol. 10, 272–277; e271. 10.1016/j.cgh.2011.10.008
    1. Ahmed A. A., Etemadmoghadam D., Temple J., Lynch A. G., Riad M., Sharma R., et al. . (2010). Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 221, 49–56. 10.1002/path.2696
    1. An Q., Liu Y., Gao Y., Huang J., Fong X., Li L., et al. . (2002). Detection of p16 hypermethylation in circulating plasma DNA of non-small cell lung cancer patients. Cancer Lett. 188, 109–114. 10.1016/S0304-3835(02)00496-2
    1. Bast R. C., Jr, Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., et al. . (1983). A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309, 883–887. 10.1056/NEJM198310133091503
    1. Bearzatto A., Conte D., Frattini M., Zaffaroni N., Andriani F., Balestra D., et al. . (2002). p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clin. Cancer Res. 8, 3782–3787.
    1. Belinsky S. A., Klinge D. M., Dekker J. D., Smith M. W., Bocklage T. J., Gilliland F. D., et al. . (2005). Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin. Cancer Res. 11, 6505–6511. 10.1158/1078-0432.CCR-05-0625
    1. Bettegowda C., Sausen M., Leary R. J., Kinde I., Wang Y., Agrawal N., et al. . (2014). Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra224. 10.1126/scitranslmed.3007094
    1. Buys S. S., Partridge E., Black A., Johnson C. C., Lamerato L., Isaacs C., et al. . (2011). Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA 305, 2295–2303. 10.1001/jama.2011.766
    1. Cancer Genome Atlas Network . (2012). Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70. 10.1038/nature11412
    1. Cancer Genome Atlas Research Network . (2011). Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615. 10.1038/nature10166
    1. Cassinotti E., Melson J., Liggett T., Melnikov A., Yi Q., Replogle C., et al. . (2011). DNA methylation patterns in blood of patients with colorectal cancer and adenomatous colorectal polyps. Int. J. Cancer 131, 1153–1157. 10.1002/ijc.26484
    1. Chetverin A. B., Chetverina H. V. (2008). Molecular colony technique: a new tool for biomedical research and clinical practice. Prog. Nucleic Acid Res. Mol. Biol. 82, 219–255. 10.1016/S0079-6603(08)00007-X
    1. Chimonidou M., Strati A., Malamos N., Georgoulias V., Lianidou E. S. (2013a). SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. Clin. Chem. 59, 270–279. 10.1373/clinchem.2012.191551
    1. Chimonidou M., Tzitzira A., Strati A., Sotiropoulou G., Sfikas C., Malamos N., et al. . (2013b). CST6 promoter methylation in circulating cell-free DNA of breast cancer patients. Clin. Biochem. 46, 235–240. 10.1016/j.clinbiochem.2012.09.015
    1. Church T. R., Wandell M., Lofton-Day C., Mongin S. J., Burger M., Payne S. R., et al. . (2014). Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 63, 317–325. 10.1136/gutjnl-2012-304149
    1. Danese E., Minicozzi A. M., Benati M., Montagnana M., Paviati E., Salvagno G. L., et al. . (2013). Epigenetic alteration: new insights moving from tissue to plasma - the example of PCDH10 promoter methylation in colorectal cancer. Br. J. Cancer 109, 807–813. 10.1038/bjc.2013.351
    1. Day E., Dear P. H., Mccaughan F. (2013). Digital PCR strategies in the development and analysis of molecular biomarkers for personalized medicine. Methods 59, 101–107. 10.1016/j.ymeth.2012.08.001
    1. Del Monte U. (2009). Does the cell number 10(9) still really fit one gram of tumor tissue? Cell Cycle 8, 505–506. 10.4161/cc.8.3.7608
    1. Devonshire A. S., Whale A. S., Gutteridge A., Jones G., Cowen S., Foy C. A., et al. . (2014). Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal. Bioanal. Chem. 406, 6499–6512. 10.1007/s00216-014-7835-3
    1. Devos T., Tetzner R., Model F., Weiss G., Schuster M., Distler J., et al. . (2009). Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin. Chem. 55, 1337–1346. 10.1373/clinchem.2008.115808
    1. Diehl F., Schmidt K., Choti M. A., Romans K., Goodman S., Li M., et al. . (2008). Circulating mutant DNA to assess tumor dynamics. Nat. Med. 14, 985–990. 10.1038/nm.1789
    1. Dong R., Yu J., Pu H., Zhang Z., Xu X. (2012). Frequent SLIT2 promoter methylation in the serum of patients with ovarian cancer. J. Int. Med. Res. 40, 681–686. 10.1177/147323001204000231
    1. Drukteinis J. S., Mooney B. P., Flowers C. I., Gatenby R. A. (2013). Beyond mammography: new frontiers in breast cancer screening. Am. J. Med. 126, 472–479. 10.1016/j.amjmed.2012.11.025
    1. El Messaoudi S., Rolet F., Mouliere F., Thierry A. R. (2013). Circulating cell free DNA: preanalytical considerations. Clin. Chim. Acta 424, 222–230. 10.1016/j.cca.2013.05.022
    1. Gloss B. S., Samimi G. (2014). Epigenetic biomarkers in epithelial ovarian cancer. Cancer Lett. 342, 257–263. 10.1016/j.canlet.2011.12.036
    1. Gormally E., Hainaut P., Caboux E., Airoldi L., Autrup H., Malaveille C., et al. . (2004). Amount of DNA in plasma and cancer risk: a prospective study. Int. J. Cancer 111, 746–749. 10.1002/ijc.20327
    1. Grutzmann R., Molnar B., Pilarsky C., Habermann J. K., Schlag P. M., Saeger H. D., et al. . (2008). Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS ONE 3:e3759. 10.1371/journal.pone.0003759
    1. Guerrero-Preston R., Hadar T., Ostrow K. L., Soudry E., Echenique M., Ili-Gangas C., et al. . (2014). Differential promoter methylation of kinesin family member 1a in plasma is associated with breast cancer and DNA repair capacity. Oncol. Rep. 32, 505–512. 10.3892/or.2014.3262
    1. Hill V. K., Ricketts C., Bieche I., Vacher S., Gentle D., Lewis C., et al. . (2011). Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res. 71, 2988–2999. 10.1158/0008-5472.CAN-10-4026
    1. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. (1991). p53 mutations in human cancers. Science 253, 49–53. 10.1126/science.1905840
    1. Hoque M. O., Feng Q., Toure P., Dem A., Critchlow C. W., Hawes S. E., et al. . (2006). Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J. Clin. Oncol. 24, 4262–4269. 10.1200/JCO.2005.01.3516
    1. Hovestadt V., Jones D. T., Picelli S., Wang W., Kool M., Northcott P. A., et al. . (2014). Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature 510, 537–541. 10.1038/nature13268
    1. Hsu H. S., Chen T. P., Hung C. H., Wen C. K., Lin R. K., Lee H. C., et al. . (2007). Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer 110, 2019–2026. 10.1002/cncr.23001
    1. Ibanez De Caceres I., Battagli C., Esteller M., Herman J. G., Dulaimi E., Edelson M. I., et al. . (2004). Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 64, 6476–6481. 10.1158/0008-5472.CAN-04-1529
    1. Independent UK Panel on Breast Cancer Screening . (2012). The benefits and harms of breast cancer screening: an independent review. Lancet 380, 1778–1786. 10.1016/S0140-6736(12)61611-0
    1. Ishikawa O., Ohigashi H., Imaoka S., Nakaizumi A., Uehara H., Kitamura T., et al. . (1999). Minute carcinoma of the pancreas measuring 1 cm or less in diameter–collective review of Japanese case reports. Hepatogastroenterology 46, 8–15.
    1. Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F. O., Hesch R. D., et al. . (2001). DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61, 1659–1665.
    1. Jiao L., Zhu J., Hassan M. M., Evans D. B., Abbruzzese J. L., Li D. (2007). K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. Pancreas 34, 55–62. 10.1097/01.mpa.0000246665.68869.d4
    1. Jung M., Klotzek S., Lewandowski M., Fleischhacker M., Jung K. (2003). Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin. Chem. 49, 1028–1029. 10.1373/49.6.1028
    1. Keeley B., Stark A., Pisanic T. R., II, Kwak R., Zhang Y., Wrangle J., et al. . (2013). Extraction and processing of circulating DNA from large sample volumes using methylation on beads for the detection of rare epigenetic events. Clin. Chim. Acta 425, 169–175. 10.1016/j.cca.2013.07.023
    1. Kneip C., Schmidt B., Seegebarth A., Weickmann S., Fleischhacker M., Liebenberg V., et al. . (2011). SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J. Thorac. Oncol. 6, 1632–1638. 10.1097/JTO.0b013e318220ef9a
    1. Kurakawa E., Shimamoto T., Utsumi K., Hirano T., Kato H., Ohyashiki K. (2001). Hypermethylation of p16(INK4a) and p15(INK4b) genes in non-small cell lung cancer. Int. J. Oncol. 19, 277–281. 10.3892/ijo.19.2.277
    1. Ladabaum U., Allen J., Wandell M., Ramsey S. (2013). Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies. Cancer Epidemiol. Biomarkers Prev. 22, 1567–1576. 10.1158/1055-9965.EPI-13-0204
    1. Lange C. P., Campan M., Hinoue T., Schmitz R. F., Van Der Meulen-De Jong A. E., Slingerland H., et al. . (2012). Genome-scale discovery of DNA-methylation biomarkers for blood-based detection of colorectal cancer. PLoS ONE 7:e50266. 10.1371/journal.pone.0050266
    1. Lee B. B., Lee E. J., Jung E. H., Chun H. K., Chang D. K., Song S. Y., et al. . (2009). Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin. Cancer Res. 15, 6185–6191. 10.1158/1078-0432.CCR-09-0111
    1. Lee T. H., Montalvo L., Chrebtow V., Busch M. P. (2001). Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion 41, 276–282. 10.1046/j.1537-2995.2001.41020276.x
    1. Lennon A. M., Wolfgang C. L., Canto M. I., Klein A. P., Herman J. M., Goggins M., et al. . (2014). The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia? Cancer Res. 74, 3381–3389. 10.1158/0008-5472.CAN-14-0734
    1. Li M., Chen W. D., Papadopoulos N., Goodman S. N., Bjerregaard N. C., Laurberg S., et al. . (2009). Sensitive digital quantification of DNA methylation in clinical samples. Nat. Biotechnol. 27, 858–863. 10.1038/nbt.1559
    1. Liggett T. E., Melnikov A., Yi Q., Replogle C., Hu W., Rotmensch J., et al. . (2011). Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol. Oncol. 120, 113–120. 10.1016/j.ygyno.2010.09.019
    1. Liggett T., Melnikov A., Yi Q. L., Replogle C., Brand R., Kaul K., et al. . (2010). Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer 116, 1674–1680. 10.1002/cncr.24893
    1. Lo Y. M., Tein M. S., Lau T. K., Haines C. J., Leung T. N., Poon P. M., et al. . (1998). Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am. J. Hum. Genet. 62, 768–775. 10.1086/301800
    1. Lofton-Day C., Model F., Devos T., Tetzner R., Distler J., Schuster M., et al. . (2008). DNA methylation biomarkers for blood-based colorectal cancer screening. Clin. Chem. 54, 414–423. 10.1373/clinchem.2007.095992
    1. Lui Y. Y., Chik K. W., Chiu R. W., Ho C. Y., Lam C. W., Lo Y. M. (2002). Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin. Chem. 48, 421–427.
    1. Melnikov A. A., Scholtens D., Talamonti M. S., Bentrem D. J., Levenson V. V. (2009b). Methylation profile of circulating plasma DNA in patients with pancreatic cancer. J. Surg. Oncol. 99, 119–122. 10.1002/jso.21208
    1. Melnikov A., Scholtens D., Godwin A., Levenson V. (2009a). Differential methylation profile of ovarian cancer in tissues and plasma. J. Mol. Diagn. 11, 60–65. 10.2353/jmoldx.2009.080072
    1. Melotte V., Yi J. M., Lentjes M., Smits K. M., Van Neste L., Niessen H. E., et al. . (2015). Spectrin repeat containing nuclear envelope 1 and Forkhead box protein E1 are promising markers for the detection of colorectal cancer in blood. Cancer Prev. Res. (Phila). 8, 157–164. 10.1158/1940-6207.CAPR-14-0198
    1. Menon U., Gentry-Maharaj A., Hallett R., Ryan A., Burnell M., Sharma A., et al. . (2009). Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 10, 327–340. 10.1016/S1470-2045(09)70026-9
    1. Menon U., Griffin M., Gentry-Maharaj A. (2014). Ovarian cancer screening–current status, future directions. Gynecol. Oncol. 132, 490–495. 10.1016/j.ygyno.2013.11.030
    1. Montavon C., Gloss B. S., Warton K., Barton C. A., Statham A. L., Scurry J. P., et al. . (2012). Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol. Oncol. 124, 582–588. 10.1016/j.ygyno.2011.11.026
    1. Nair S. S., Coolen M. W., Stirzaker C., Song J. Z., Statham A. L., Strbenac D., et al. . (2011). Comparison of methyl-DNA immunoprecipitation (MeDIP) and methyl-CpG binding domain (MBD) protein capture for genome-wide DNA methylation analysis reveal CpG sequence coverage bias. Epigenetics 6, 34–44. 10.4161/epi.6.1.13313
    1. Ng C. S., Zhang J., Wan S., Lee T. W., Arifi A. A., Mok T., et al. . (2002). Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer. J. Surg. Oncol. 79, 101–106. 10.1002/jso.10046
    1. Ng E. K., Leung C. P., Shin V. Y., Wong C. L., Ma E. S., Jin H. C., et al. . (2011). Quantitative analysis and diagnostic significance of methylated SLC19A3 DNA in the plasma of breast and gastric cancer patients. PLoS ONE 6:e22233. 10.1371/journal.pone.0022233
    1. Nishihara R., Wu K., Lochhead P., Morikawa T., Liao X., Qian Z. R., et al. . (2013). Long-term colorectal-cancer incidence and mortality after lower endoscopy. N. Engl. J. Med. 369, 1095–1105. 10.1056/NEJMoa1301969
    1. Nones K., Waddell N., Song S., Patch A. M., Miller D., Johns A., et al. . (2014). Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Int. J. Cancer 135, 1110–1118. 10.1002/ijc.28765
    1. Ostrow K. L., Hoque M. O., Loyo M., Brait M., Greenberg A., Siegfried J. M., et al. . (2010). Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin. Cancer Res. 16, 3463–3472. 10.1158/1078-0432.CCR-09-3304
    1. Ostrow K. L., Michailidi C., Guerrero-Preston R., Hoque M. O., Greenberg A., Rom W., et al. . (2013). Cigarette smoke induces methylation of the tumor suppressor gene NISCH. Epigenetics 8, 383–388. 10.4161/epi.24195
    1. Pack S. C., Kim H. R., Lim S. W., Kim H. Y., Ko J. Y., Lee K. S., et al. . (2013). Usefulness of plasma epigenetic changes of five major genes involved in the pathogenesis of colorectal cancer. Int. J. Colorectal Dis. 28, 139–147. 10.1007/s00384-012-1566-8
    1. Pan H., Chen L., Dogra S., Teh A. L., Tan J. H., Lim Y. I., et al. . (2012). Measuring the methylome in clinical samples: improved processing of the Infinium Human Methylation450 BeadChip Array. Epigenetics 7, 1173–1187. 10.4161/epi.22102
    1. Park J. W., Baek I. H., Kim Y. T. (2012). Preliminary study analyzing the methylated genes in the plasma of patients with pancreatic cancer. Scand. J. Surg. 101, 38–44. 10.1177/145749691210100108
    1. Pedersen S. K., Mitchell S. M., Graham L. D., Mcevoy A., Thomas M. L., Baker R. T., et al. . (2014). CAHM, a long non-coding RNA gene hypermethylated in colorectal neoplasia. Epigenetics 9, 1071–1082. 10.4161/epi.29046
    1. Ponomaryova A. A., Rykova E. Y., Cherdyntseva N. V., Skvortsova T. E., Dobrodeev A. Y., Zav'yalov A. A., et al. . (2011). RARbeta2 gene methylation level in the circulating DNA from blood of patients with lung cancer. Eur. J. Cancer Prev. 20, 453–455. 10.1097/CEJ.0b013e3283498eb4
    1. Ponomaryova A. A., Rykova E. Y., Cherdyntseva N. V., Skvortsova T. E., Dobrodeev A. Y., Zav'yalov A. A., et al. . (2013). Potentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patients. Lung Cancer 81, 397–403. 10.1016/j.lungcan.2013.05.016
    1. Potter N. T., Hurban P., White M. N., Whitlock K. D., Lofton-Day C. E., Tetzner R., et al. . (2014). Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. Clin. Chem. 60, 1183–1191. 10.1373/clinchem.2013.221044
    1. Powrozek T., Krawczyk P., Kucharczyk T., Milanowski J. (2014). Septin 9 promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer: preliminary report. Med. Oncol. 31, 917. 10.1007/s12032-014-0917-4
    1. Radpour R., Barekati Z., Kohler C., Lv Q., Burki N., Diesch C., et al. . (2011). Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS ONE 6:e16080. 10.1371/journal.pone.0016080
    1. Rauh-Hain J. A., Krivak T. C., Del Carmen M. G., Olawaiye A. B. (2011). Ovarian cancer screening and early detection in the general population. Rev. Obstet. Gynecol. 4, 15–21. 10.3909/riog0143
    1. Rykova E. Y., Morozkin E. S., Ponomaryova A. A., Loseva E. M., Zaporozhchenko I. A., Cherdyntseva N. V., et al. . (2012). Cell-free and cell-bound circulating nucleic acid complexes: mechanisms of generation, concentration and content. Expert Opin. Biol. Ther. 12(Suppl 1.), S141–S153. 10.1517/14712598.2012.673577
    1. Rykova E. Y., Skvortsova T. E., Laktionov P. P., Tamkovich S. N., Bryzgunova O. E., Starikov A. V., et al. . (2004). Investigation of tumor-derived extracellular DNA in blood of cancer patients by methylation-specific PCR. Nucleosides Nucleotides Nucleic Acids 23, 855–859. 10.1081/NCN-200026031
    1. Schmidt K., Diehl F. (2007). A blood-based DNA test for colorectal cancer screening. Discov. Med. 7, 7–12.
    1. Scholefield J. H., Moss S. M., Mangham C. M., Whynes D. K., Hardcastle J. D. (2012). Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut 61, 1036–1040. 10.1136/gutjnl-2011-300774
    1. Schrader C., Schielke A., Ellerbroek L., Johne R. (2012). PCR inhibitors - occurrence, properties and removal. J. Appl. Microbiol. 113, 1014–1026. 10.1111/j.1365-2672.2012.05384.x
    1. Schwarzenbach H., Hoon D. S., Pantel K. (2011). Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11, 426–437. 10.1038/nrc3066
    1. Shaukat A., Mongin S. J., Geisser M. S., Lederle F. A., Bond J. H., Mandel J. S., et al. . (2013). Long-term mortality after screening for colorectal cancer. N. Engl. J. Med. 369, 1106–1114. 10.1056/NEJMoa1300720
    1. Siegel R., Ma J., Zou Z., Jemal A. (2014). Cancer statistics, 2014. CA Cancer J. Clin. 64, 9–29. 10.3322/caac.21208
    1. Skvortsova T. E., Rykova E. Y., Tamkovich S. N., Bryzgunova O. E., Starikov A. V., Kuznetsova N. P., et al. . (2006). Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br. J. Cancer 94, 1492–1495. 10.1038/sj.bjc.6603117
    1. Takane K., Midorikawa Y., Yagi K., Sakai A., Aburatani H., Takayama T., et al. . (2014). Aberrant promoter methylation of PPP1R3C and EFHD1 in plasma of colorectal cancer patients. Cancer Med. 3, 1235–1245. 10.1002/cam4.273
    1. Tamkovich S. N., Litviakov N. V., Bryzgunova O. E., Dobrodeev A. Y., Rykova E. Y., Tuzikov S. A., et al. . (2008). Cell-surface-bound circulating DNA as a prognostic factor in lung cancer. Ann. N.Y. Acad. Sci. 1137, 214–217. 10.1196/annals.1448.042
    1. Thakur B. K., Zhang H., Becker A., Matei I., Huang Y., Costa-Silva B., et al. . (2014). Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 24, 766–769. 10.1038/cr.2014.44
    1. Umbricht C. B., Evron E., Gabrielson E., Ferguson A., Marks J., Sukumar S. (2001). Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 20, 3348–3353. 10.1038/sj.onc.1204438
    1. Usadel H., Brabender J., Danenberg K. D., Jeronimo C., Harden S., Engles J., et al. . (2002). Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res. 62, 371–375.
    1. Vogelstein B., Papadopoulos N., Velculescu V. E., Zhou S., Diaz L. A., Jr, Kinzler K. W. (2013). Cancer genome landscapes. Science 339, 1546–1558. 10.1126/science.1235122
    1. Wang Y. C., Hsu H. S., Chen T. P., Chen J. T. (2006). Molecular diagnostic markers for lung cancer in sputum and plasma. Ann. N.Y. Acad. Sci. 1075, 179–184. 10.1196/annals.1368.024
    1. Warren J. D., Xiong W., Bunker A. M., Vaughn C. P., Furtado L. V., Roberts W. L., et al. . (2011). Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 9:133. 10.1186/1741-7015-9-133
    1. Warton K., Lin V., Navin T., Armstrong N. J., Kaplan W., Ying K., et al. . (2014). Methylation-capture and Next-Generation Sequencing of free circulating DNA from human plasma. BMC Genomics 15:476. 10.1186/1471-2164-15-476
    1. Zhang Q., Hu G., Yang Q., Dong R., Xie X., Ma D., et al. . (2013). A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. Gynecol. Oncol. 130, 132–139. 10.1016/j.ygyno.2013.04.048
    1. Zhang Y., Wang R., Song H., Huang G., Yi J., Zheng Y., et al. . (2011). Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett. 303, 21–28. 10.1016/j.canlet.2010.12.011
    1. Zhou F., Ma M., Tao G., Chen X., Xie W., Wang Y., et al. . (2014). Detection of circulating methylated opioid binding protein/cell adhesion molecule-like gene as a biomarker for ovarian carcinoma. Clin. Lab. 60, 759–765.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit